The Addition of Dydrogesterone after Frozen Embryo Transfer in Hormonal Substituted Cycles with Low Progesterone Levels

 

 Permissions and Reprints

Abstract

Objective To determine whether a rescue strategy using dydrogesterone (DYD) could improve the outcomes of frozen embryo transfer cycles (FET) with low progesterone (P4) levels on the day of a blastocyst transfer.

Methods Retrospective cohort study including FET cycles performed between July 2019 and October 2020 following an artificial endometrial preparation cycle using estradiol valerate and micronized vaginal P4 (400 mg twice daily). Whenever the serum P4 value was below 10 ng/mL on the morning of the planned transfer, DYD 10 mg three times a day was added as supplementation. The primary endpoint was ongoing pregnancy beyond 10 weeks. The sample was subdivided into two groups according to serum P4 on the day of FET: low (< 10 ng/mL, with DYD supplementation) or normal (above 10 ng/mL). We performed linear or logistic generalized estimating equations (GEE), as appropriate.

Results We analyzed 304 FET cycles from 241 couples, 11.8% (n = 36) of which had serum P4 below 10 ng/mL on the FET day. Baseline clinical data of patients was comparable between the study groups.

Overall, 191 cycles (62.8%) had a biochemical pregnancy, of which 131 (44,1%) were ongoing pregnancies, with a 29,8% miscarriage rate. We found no statistically significant differences in the hCG positive (63 vs 64%) or ongoing pregnancy rates (50 vs 43,3%) between those FETs with low or normal serum P4 values, even after multivariable logistic regression modelling.

Conclusion Our results indicate that DYD 10 mg three times a day administered in women who perform FET with P4 serum levels < 10 ng/mL, allows this group to have pregnancy rates beyond 12 weeks at least as good as those with serum levels above 10 ng/mL.

Resumo

Objetivo Determinar se uma estratégia de resgate usando didrogesterona (DYD) pode melhorar os resultados dos ciclos de transferência de embriões congelados (TEC) com baixos níveis de progesterona (P4) no dia de uma transferência de blastocisto.

Métodos Estudo de coorte retrospectivo que incluiu ciclos TEC realizados entre julho de 2019 e outubro de 2020 após um ciclo de preparação endometrial artificial usando valerato de estradiol e P4 vaginal micronizado (400 mg duas vezes ao dia). Sempre que o valor de P4 sérico estava abaixo de 10 ng/mL na manhã da transferência planejada, adicionou-se 10 mg de DYD tri-diário como suplementação. O desfecho primário foi gravidez evolutiva após 10 semanas. A amostra foi subdividida em dois grupos de acordo com o P4 sérico no dia da TEC: baixo (< 10 ng/mL, com suplementação de DYD) ou normal (acima de 10 ng/mL). Realizamos equações de estimativa generalizada linear ou logística (GEE), conforme apropriado.

Resultados Analisaram-se 304 ciclos de FET de 241 casais, dos quais 11,8% (n = 36) tinham valores de P4 sérico abaixo de 10 ng/mL no dia da TEC. Os dados clínicos e demográficos dos pacientes eram comparáveis entre os grupos.

Globalmente, 191 ciclos (62,8%) tiveram uma gravidez bioquímica, dos quais 131 (44,1%) foram gestações em curso, com uma taxa de aborto espontâneo de 29,8%. Não encontramos diferenças estatisticamente significativas na taxa de gravidez bioquímica (63 vs. 64%) ou nas taxas de gravidez evolutiva (50 vs. 43,3%) entre TEC com valores séricos de P4 baixos ou normais, mesmo após modelação com regressão logística multivariável.

Conclusão Nossos resultados indicam que a suplementação com DYD 10 mg três vezes ao dia em mulheres com níveis séricos de P4 abaixo de 10 ng/mL em ciclos de TEC substituídos parecem conseguir resultados pelo menos tão bons como nos ciclos com valores superiores para taxas de gravidez em curso além de 12 semanas.

Contributions

Jose Metello: conceived the presented idea; retrieved the data; performed the computations. Claudia Tomas: developed the theoretical formalism. Pedro Ferreira: retrieved the data. Samuel Santos-Ribeiro: conceived the presented idea; performed the computations; supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.

Publication History

Received: 06 December 2021

Accepted: 18 April 2022

Article published online:
29 November 2022

© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

• References

• 1 De Geyter C, Calhaz-Jorge C, Kupka MS, Wyns C, Mocanu E, Motrenko T. et al; European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). ART in Europe, 2014: results generated from European registries by ESHRE: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2018; 33 (09) 1586-1601 DOI: 10.1093/humrep/dey242.
  CrossrefPubMedGoogle Scholar
• 2 Ghobara T, Gelbaya TA, Ayeleke RO. Cycle regimens for frozen-thawed embryo transfer. Cochrane Database Syst Rev 2017; 7 (07) CD003414 DOI: 10.1002/14651858.CD003414.pub3.
  CrossrefPubMedGoogle Scholar
• 3 Groenewoud ER, Cohlen BJ, Macklon NS. Programming the endometrium for deferred transfer of cryopreserved embryos: hormone replacement versus modified natural cycles. Fertil Steril 2018; 109 (05) 768-774 DOI: 10.1016/j.fertnstert.2018.02.135.
  CrossrefPubMedGoogle Scholar
• 4 Yarali H, Polat M, Mumusoglu S, Yarali I, Bozdag G. Preparation of endometrium for frozen embryo replacement cycles: a systematic review and meta-analysis. J Assist Reprod Genet 2016; 33 (10) 1287-1304 DOI: 10.1007/s10815-016-0787-0.
  CrossrefPubMedGoogle Scholar
• 5 Jing S, Li XF, Zhang S, Gong F, Lu G, Lin G. Increased pregnancy complications following frozen-thawed embryo transfer during an artificial cycle. J Assist Reprod Genet 2019; 36 (05) 925-933 DOI: 10.1007/s10815-019-01420-1.
  CrossrefPubMedGoogle Scholar
• 6 Ginström Ernstad E, Wennerholm UB, Khatibi A, Petzold M, Bergh C. Neonatal and maternal outcome after frozen embryo transfer: Increased risks in programmed cycles. Am J Obstet Gynecol 2019; 221 (02) 126.e1-126.e18 DOI: 10.1016/j.ajog.2019.03.010.
  CrossrefPubMedGoogle Scholar
• 7 Roque M, Bedoschi G, Cecchino GN, Esteves SC. Fresh versus frozen blastocyst transfer. Lancet 2019; 394 (10205): 1227-1228 DOI: 10.1016/S0140-6736(19)31393-5.
  CrossrefPubMedGoogle Scholar
• 8 Neumann K, Depenbusch M, Schultze-Mosgau A, Griesinger G. Characterization of early pregnancy placental progesterone production by use of dydrogesterone in programmed frozen-thawed embryo transfer cycles. Reprod Biomed Online 2020; 40 (05) 743-751 DOI: 10.1016/j.rbmo.2020.01.019.
  CrossrefPubMedGoogle Scholar
• 9 Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973; 115 (06) 759-765 DOI: 10.1016/0002-9378(73)90517-6.
  CrossrefPubMedGoogle Scholar
• 10 van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015; (07) CD009154 DOI: 10.1002/14651858.CD009154.pub3.
  CrossrefPubMedGoogle Scholar
• 11 Casper RF, Yanushpolsky EH. Optimal endometrial preparation for frozen embryo transfer cycles: window of implantation and progesterone support. Fertil Steril 2016; 105 (04) 867-872 DOI: 10.1016/j.fertnstert.2016.01.006.
  CrossrefPubMedGoogle Scholar
• 12 Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C. et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online 2019; 38 (02) 249-259 DOI: 10.1016/j.rbmo.2018.11.017.
  CrossrefPubMedGoogle Scholar
• 13 Labarta E, Mariani G, Holtmann N, Celada P, Remohí J, Bosch E. Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod 2017; 32 (12) 2437-2442 DOI: 10.1093/humrep/dex316.
  CrossrefPubMedGoogle Scholar
• 14 Yovich JL, Conceicao JL, Stanger JD, Hinchliffe PM, Keane KN. Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement. Reprod Biomed Online 2015; 31 (02) 180-191 DOI: 10.1016/j.rbmo.2015.05.005.
  CrossrefPubMedGoogle Scholar
• 15 Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993; 16 (03) 185-202 DOI: 10.1016/0378-5122(93)90064-o.
  CrossrefPubMedGoogle Scholar
• 16 Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod 2017; 32 (05) 1019-1027 DOI: 10.1093/humrep/dex023.
  CrossrefPubMedGoogle Scholar
• 17 Rashidi BH, Ghazizadeh M, Nejad EST, Bagheri M, Gorginzadeh M. Oral dydrogesterone for luteal support in frozen-thawed embryo transfer artificial cycles: a pilot randomized controlled trial. Asian Pac J Reprod 2016; 5 (06) 490-494 DOI: 10.1016/j.apjr.2016.10.002.
  CrossrefPubMedGoogle Scholar
• 18 Gaggiotti-Marre S, Martinez F, Coll L, Garcia S, Álvarez M, Parriego M. et al. Low serum progesterone the day prior to frozen embryo transfer of euploid embryos is associated with significant reduction in live birth rates. Gynecol Endocrinol 2019; 35 (05) 439-442 DOI: 10.1080/09513590.2018.1534952.
  CrossrefPubMedGoogle Scholar
• 19 Labarta E, Mariani G, Paolelli S, Rodriguez-Varela C, Vidal C, Giles J. et al. Impact of low serum progesterone levels on the day of embryo transfer on pregnancy outcome: a prospective cohort study in artificial cycles with vaginal progesterone. Hum Reprod 2021; 36 (03) 683-692 DOI: 10.1093/humrep/deaa322.
  CrossrefPubMedGoogle Scholar
• 20 Brady PC, Kaser DJ, Ginsburg ES, Ashby RK, Missmer SA, Correia KF. et al. Serum progesterone concentration on day of embryo transfer in donor oocyte cycles. J Assist Reprod Genet 2014; 31 (05) 569-575 DOI: 10.1007/s10815-014-0199-y.
  CrossrefPubMedGoogle Scholar
• 21 Basnayake SK, Volovsky M, Rombauts L, Osianlis T, Vollenhoven B, Healey M. Progesterone concentrations and dosage with frozen embryo transfers - What's best?. Aust N Z J Obstet Gynaecol 2018; 58 (05) 533-538 DOI: 10.1111/ajo.12757.
  CrossrefPubMedGoogle Scholar
• 22 Alsbjerg B, Thomsen L, Elbaek HO, Laursen R, Povlsen BB, Haahr T. et al. Progesterone levels on pregnancy test day after hormone replacement therapy-cryopreserved embryo transfer cycles and related reproductive outcomes. Reprod Biomed Online 2018; 37 (05) 641-647 DOI: 10.1016/j.rbmo.2018.08.022.
  CrossrefPubMedGoogle Scholar
• 23 Cédrin-Durnerin I, Isnard T, Mahdjoub S, Sonigo C, Seroka A, Comtet M. et al. Serum progesterone concentration and live birth rate in frozen-thawed embryo transfers with hormonally prepared endometrium. Reprod Biomed Online 2019; 38 (03) 472-480 DOI: 10.1016/j.rbmo.2018.11.026.
  CrossrefPubMedGoogle Scholar
• 24 Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW. et al. Classification and pharmacology of progestins. Maturitas 2003; 46 (Suppl. 01) S7-S16 DOI: 10.1016/j.maturitas.2003.09.014.
  CrossrefPubMedGoogle Scholar
• 25 Stanczyk FZ, Hapgood JP, Winer S, Mishell Jr DR. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013; 34 (02) 171-208 DOI: 10.1210/er.2012-1008.
  CrossrefPubMedGoogle Scholar
• 26 Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard?. Fertil Steril 2018; 109 (05) 756-762 DOI: 10.1016/j.fertnstert.2018.03.034.
  CrossrefPubMedGoogle Scholar
• 27 Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod 2011; 26 (06) 1270-1283 DOI: 10.1093/humrep/der037.
  CrossrefPubMedGoogle Scholar
• 28 Metello J, Tomás C, Ferreira P, Bravo I, Branquinho M, Santos-Ribeiro S. Impact of plasmatic progesterone on the day of frozen embryo transfer in hormone-induced cycles. Rev Bras Ginecol Obstet 2021; 43 (08) 608-615 DOI: 10.1055/s-0041-1735229.
  Article in Thieme ConnectPubMedGoogle Scholar
• 29 Yland J, Messerlian C, Mínguez-Alarcón L, Ford JB, Hauser R, Williams PL. EARTH Study Team. Methodological approaches to analyzing IVF data with multiple cycles. Hum Reprod 2019; 34 (03) 549-557 DOI: 10.1093/humrep/dey374.
  CrossrefPubMedGoogle Scholar
• 30 Kofinas JD, Blakemore J, McCulloh DH, Grifo J. Serum progesterone levels greater than 20 ng/dl on day of embryo transfer are associated with lower live birth and higher pregnancy loss rates. J Assist Reprod Genet 2015; 32 (09) 1395-1399 DOI: 10.1007/s10815-015-0546-7.
  CrossrefPubMedGoogle Scholar
• 31 Atzmon Y, Aslih N, Estrada D, Bilgory A, Ellenbogen A, Shalom-Paz E. Comparable outcomes using oral dydrogesterone vs. micronized vaginal progesterone in frozen embryo transfer: a retrospective cohort study. Reprod Sci 2021; 28 (07) 1874-1881 DOI: 10.1007/s43032-020-00376-3.
  CrossrefPubMedGoogle Scholar
• 32 Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 2005; 97 (05) 416-420 DOI: 10.1016/j.jsbmb.2005.08.012.
  CrossrefPubMedGoogle Scholar
• 33 Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol 2007; 23 (Suppl. 01) 68-72 DOI: 10.1080/09513590701584857.
  CrossrefPubMedGoogle Scholar
• 34 Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril 2011; 95 (06) 1961-1965 DOI: 10.1016/j.fertnstert.2011.01.148.
  CrossrefPubMedGoogle Scholar
• 35 Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2015; 186: 49-53 DOI: 10.1016/j.ejogrb.2014.11.002.
  CrossrefPubMedGoogle Scholar
• 36 Saharkhiz N, Zamaniyan M, Salehpour S, Zadehmodarres S, Hoseini S, Cheraghi L. et al. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles. Gynecol Endocrinol 2016; 32 (03) 213-217 DOI: 10.3109/09513590.2015.1110136.
  CrossrefPubMedGoogle Scholar
• 37 Zarei A, Sohail P, Parsanezhad ME, Alborzi S, Samsami A, Azizi M. Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial. Arch Gynecol Obstet 2017; 295 (01) 239-246 DOI: 10.1007/s00404-016-4217-4.
  CrossrefPubMedGoogle Scholar
• 38 Álvarez M, Gaggiotti-Marre S, Martínez F, Coll L, García S, González-Foruria I. et al. Individualised luteal phase support in artificially prepared frozen embryo transfer cycles based on serum progesterone levels: a prospective cohort study. Hum Reprod 2021; 36 (06) 1552-1560 DOI: 10.1093/humrep/deab031.
  CrossrefPubMedGoogle Scholar
• 39 Vuong LN, Pham TD, Le KTQ, Ly TT, Le HL, Nguyen DT. et al. Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Hum Reprod 2021; 36 (07) 1821-1831 DOI: 10.1093/humrep/deab093.
  CrossrefPubMedGoogle Scholar
• 40 Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev 2009; 85 (06) 375-377 DOI: 10.1016/j.earlhumdev.2008.12.016.
  CrossrefPubMedGoogle Scholar
• 41 Zaqout M, Aslem E, Abuqamar M, Abughazza O, Panzer J, De Wolf D. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr Cardiol 2015; 36 (07) 1483-1488 DOI: 10.1007/s00246-015-1190-9.
  CrossrefPubMedGoogle Scholar
• 42 Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C, Olofsson JI, Driessen S. et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One 2020; 15 (11) e0241044 DOI: 10.1371/journal.pone.0241044.
  CrossrefPubMedGoogle Scholar